Pharmabiz6d
ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours
ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...
Pharmabiz5d
European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC
European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...
Yahoo Finance4d
BriaCell Therapeutics Corp. (BCTX)
After hours: March 11 at 7:41:59 PM EDT Loading Chart for BCTX ...